CHICAGO—Findings from an expanded phase I study in 107 patients with metastatic melanoma suggest that PD-1 inhibition with the novel agent nivolumab could bring extended remissions. Sarah Maxwell hear
CHICAGO—Findings from an expanded phase I study in 107 patients with metastatic melanoma suggest that PD-1 inhibition with the novel agent nivolumab could bring extended remissions. Sarah Maxwell heard the latest at the American Society of Clinical Oncology’s 2013 meeting in Chicago from Dr. Mario Sznol MD, Clinical Research Program Leader at Yale Cancer Center, New Haven, CT and Dr. Lynn Schuchter Chief of Hematolgy/Oncology at the Abramson Cancer Center, University of Pennsylvania, Philadelphia.